Skip to main content
TipRanks
Go Ultimate75% OFF

CNS Pharmaceuticals (CNSP) Stock Price & Analysis

1,098 Followers

CNSP Stock Chart & Stats

$2.89-$0.73(-20.17%)
At close: 4:00 PM EST
$3$4$5$6Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$2.89 - $3.70
52-Week Range
$1.90 - $10.54
Previous Close
$3.62
Volume
N/A
Average Volume (3M)
13.01K
Market Cap
$4.22M
Enterprise Value
$12.70M
Total Cash (Recent Filing)
$17.21M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
3.53
Next Earnings
Nov 18, 2026 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Minimal debt reduces interest obligations and balance-sheet pressure while preserving flexibility to fund clinical programs. The improved equity and asset base since 2023 also indicates that financing has repaired the capital structure, supporting near-term operational resilience.

Improved Liquidity

The substantial cash increase strengthens the company’s ability to continue planned operations without an immediate funding requirement. Management believes resources can fund operations beyond the next twelve months, extending runway for clinical and strategic execution.

Pipeline Expansion Potential

Advanced discussions around a differentiated therapeutic asset could broaden the pipeline beyond existing programs and create a platform for future clinical development. If completed, such a transaction could improve strategic relevance and provide additional long-term growth avenues.

Bears Say

No Commercial Revenue

Without product revenue, the company has not yet demonstrated commercial demand or an operating business model that can independently fund development. The absence of recurring sales leaves future value dependent on clinical progress, partnerships, financing, or eventual commercialization.

Persistent Cash Burn

Ongoing negative operating and free cash flow means the company consumes cash rather than generating funds internally. Continued development therefore depends on maintaining access to external financing, which can constrain strategic flexibility and increase dilution risk over time.

Potential Share Dilution

Expanding equity-plan authorization gives the company flexibility to compensate employees and management, but it also creates additional potential dilution for existing shareholders. This may reduce each holder’s ownership percentage if the newly authorized shares are issued.

CNS Pharmaceuticals News

CNSP FAQ

What was CNS Pharmaceuticals’s price range in the past 12 months?
CNS Pharmaceuticals lowest stock price was $1.90 and its highest was $10.54 in the past 12 months.
What is CNS Pharmaceuticals’s market cap?
CNS Pharmaceuticals’s market cap is $4.22M.
When is CNS Pharmaceuticals’s upcoming earnings report date?
CNS Pharmaceuticals’s next earnings report is estimated for Nov 18, 2026 (not yet confirmed), which is in 2 days.
How were CNS Pharmaceuticals’s earnings last quarter?
CNS Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.14.
Is CNS Pharmaceuticals overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does CNS Pharmaceuticals pay dividends?
CNS Pharmaceuticals does not currently pay dividends.
What is CNS Pharmaceuticals’s EPS estimate?
CNS Pharmaceuticals’s EPS estimate is -0.27.
How many shares outstanding does CNS Pharmaceuticals have?
CNS Pharmaceuticals has 1,461,449 shares outstanding.
What happened to CNS Pharmaceuticals’s price movement after its last earnings report?
CNS Pharmaceuticals reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went down -8.893%.
Which hedge fund is a major shareholder of CNS Pharmaceuticals?
Hedge funds hold CNS Pharmaceuticals shares: the largest hedge-fund position in CNS Pharmaceuticals is 67,934,160 shares, and hedge funds decreased their holdings by 236.0 shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology